TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Phase I: Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma, Hodgkin's Disease or multiple myeloma (defined by World Health Organization (WHO) criteria).~Phase II: Patients must have histologically confirmed relapsed or refractory T-Cell Lymphoma (as defined by WHO criteria).~* Must have received first line chemotherapy. No upper limit for the number of prior therapies~* Evaluable Disease~* Age ≥18 years~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Patients must have adequate organ and marrow function as defined in the protocol~* Adequate Contraception~* Ability to understand and the willingness to sign a written informed consent document~* Inclusion Criteria for Multiple Myeloma patients specified in the protocol~Exclusion Criteria:~* Prior Therapy~  * Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier~ * Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs~ * No other investigational agents are allowed~* Central nervous system metastases, including lymphomatous meningitis~* History of allergic reactions to Pralatrexate or Romidepsin~* Uncontrolled intercurrent illness~* Pregnant women~* Nursing women~* Current malignancy or history of a prior malignancy, as outlined in the protocol~* Patient known to be Human Immunodeficiency Virus (HIV)-positive~* Active Hepatitis A, Hepatitis B, or Hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: Schedule A (Type: EXPERIMENTAL): Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
- Phase I: Schedule B (Type: EXPERIMENTAL): Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
- Phase II (Type: EXPERIMENTAL): Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH)~* Stable lipid-lowering therapy for 12 weeks~* Stable weight for 6 weeks~* Stable low fat diet for 8 weeks~Exclusion Criteria:~* Significant health problems in the recent past including heart attack, stroke, blood disorders, cancer, or digestive problems

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo as a subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject age 18 years or older, who requires Humira 40 mg SC every other week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance with the local Humira label.~* Subject must be a current, on-label user of Humira who rates his/her average Humira injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve subject who requires initiation of on-label treatment with Humira.~* Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR classification criteria or the ACR/EULAR 2010 criteria,~* Female subjects are either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least one method of birth control throughout the study and for at least 70 days after the last dose of study drug.~* All female subjects of childbearing potential must have a negative test for pregnancy on a serum sample at Screening and prior to study drug dosing on a urine sample obtained at Visit 1.~Exclusion Criteria:~* Subject has been treated with any investigational drug of a chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Visit 1.~* Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit 1.~* Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).~* Known hypersensitivity to adalimumab or its excipients.~* History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Current formulation adalimumab (Type: ACTIVE_COMPARATOR): One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
- New formulation of adalimumab (Type: EXPERIMENTAL): One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial except for protocol described pre-screening activities which require a separate informed consent. - Male or female, aged 18-75 years (both inclusive) (for Japan: male or female aged 20-75 years (both inclusive)) at the time of signing informed consent - Local histological diagnosis of NASH followed by histological confirmation of NASH based on central pathologist evaluation of a liver biopsy obtained up to 21 weeks before screening - Histologic evidence of NASH based on central pathologist evaluation of a liver biopsy obtained up to 21 weeks before screening. - NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on central pathologist evaluation Exclusion Criteria: - Known or suspected abuse of alcohol (above 20 g/day for women or above 30 g/day for men), alcohol dependence\* or narcotics. (\* = assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)) - Diagnosis of type 1 diabetes according to medical records - HbA1c above 10% at screening - History or presence of pancreatitis (acute or chronic) - Calcitonin equal or above 50 ng/L at screening - Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative - Body Mass Index (BMI) ≤ 25.0 kg/sqm at the screening visit (visit 1) - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0,1 mg (Type: EXPERIMENTAL): None
- Semaglutide 0,2 mg (Type: EXPERIMENTAL): None
- Semaglutide 0,4 mg (Type: EXPERIMENTAL): None
- Placebo 1 (Type: PLACEBO_COMPARATOR): None
- Placebo 2 (Type: PLACEBO_COMPARATOR): None
- Placebo 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics as Adjuvant Treatment for Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 65 years old, with history of sexual activity, premenopausal women；~2. Nugent Score ≥ 7 for diagnosing BV；~3. Sign informed consent.~Exclusion Criteria:~1. mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection or gonococcal vaginitis;~2. History of systemic organic diseases or psychiatric diseases;~3. Planning for or during pregnancy, lactation, menstruation;~4. within 5 days of onset of the disease, any antibiotics has been used;~5. Long-term use of contraceptives or immunosuppressant;~6. Anaphylactic constitution or allergic to known ingredients of research drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics and Metronidazole (Type: EXPERIMENTAL): Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
- Metronidazole vaginal (Type: ACTIVE_COMPARATOR): Metronidazole vaginal suppositories(1 suppositories,qd,7 days )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating Online Weight Management With Primary Care Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. upcoming or recent visit at primary care practice affiliated with Brigham and Women's Hospital~2. age 20-70~3. diagnosis of type 2 diabetes and/or hypertension~4. BMI \>= 27 and \< 40 kg/m2~5. motivated to lose weight~6. valid email address and access the Internet using a computer, tablet, or smartphone~7. English or Spanish-speaking~Exclusion Criteria:~1. on insulin for treatment of their diabetes 2. MI, stroke, or atherosclerotic cardiovascular disease (ASCVD) procedure in last 6 months 3. Unstable angina 4. Currently pregnant or planning to become pregnant during the study period 5. Currently lactating 5. Has had bariatric surgery or planning to have bariatric surgery 6. \>5% weight loss in the last 6 months 7. Severe psychiatric illness or impaired mental status 8. Active or diagnosed history of and/or self-reported history of eating disorders 9. Self-reported average consumption of \> 14 alcoholic drinks/week 10. Any serious medical condition that would affect weight loss or for which weight loss is contraindicated, including active cancer (excluding non-melanoma skin cancer) or currently being treated for cancer, end stage renal disease (ESRD) on dialysis, etc.~11. On comfort care measures, hospice, or in nursing home 12. Participating in a contra-indicative research study 13. Use of prescription or over-the-counter weight loss medications or an all-liquid diet program in the last 6 months or currently 14. Any other medical contraindication for weight loss or physical activity, or any other reason that the PCP or their delegate (e.g., LPN or RN) did not deem the patient appropriate for the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Online Program Only (Type: EXPERIMENTAL): Patients will use an online weight management program called BMIQ, with minimal additional support.
- Combined Intervention (Type: EXPERIMENTAL): Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
- Usual Care (Type: NO_INTERVENTION): Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The pathological type is non keratinized carcinoma (according to the pathological classification of World, Health, Organization, WHO)~2. Overall Stage III-IVB (according to the seventh edition of AJCC staging system).~3. Age between 18-65 years old.~4. There is no evidence of distant metastasis.~5. Eastern Cooperative Oncology Group performance status 0 or 1.~6. Normal marrow function: white blood count \> 4 \* 109/L, hemoglobin \> 90g/L, and platelet count \> 100 \* 109/L.~7. Normal liver function: total bilirubin (TBIL) and alanine aminotransferase (ALT) \<2 times the normal values.~8. Normal renal function: creatinine (Cr) \<1.5 times the normal value.~9. The patient must be the basic content of this research and the defendant signed the informed consent.~Exclusion Criteria:~1. The pathological type is WHO squamous cell carcinoma or squamous cell carcinoma.~2. Age \> 65 years old, or \< 18 yeas old.~3. The purpose of treatment is palliative.~4. There was a history of malignancy, except for adequately treated basal cell carcinoma or squamous cell carcinoma, and carcinoma in situ of the cervix.~5. Women who are pregnant or lactating (for women of child-bearing age) should consider pregnancy tests; effective contraception should be emphasized during treatment）.~6. Previously received radiation therapy .~7. Primary and neck metastases were treated with chemotherapy or surgery.~8. Accompanied by other serious diseases may pose a greater risk or impact on test compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experience group 1 (Type: EXPERIMENTAL): The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
- Experience group 2 (Type: EXPERIMENTAL): The dose of lobaplatin is on d1,d22,d43.
- Experience group 3 (Type: EXPERIMENTAL): The dose of lobaplatin is on d1,d22,d43.
- Experience group 4 (Type: EXPERIMENTAL): The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
- Experience group 5 (Type: EXPERIMENTAL): The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
- Experience group 6 (Type: EXPERIMENTAL): The dose of lobaplatin is 50mg/m2 on d1,d22,d43.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for surgery under general anaesthesia for laminectomy or laminoplasty;~* American Society of Anaesthesiologists (ASA) classification of I or II;~* Age 18 to 64 years;~* Participates with an anticipated full recovery within 2 hours postoperatively.~Exclusion Criteria:~* Patient refusal;~* Participants who cannot use a patient-controlled analgesia (PCA) device and cannot understand the instructions of a Visual Analogue Score (VAS);~* Previous history of spinal surgery;~* Allergy to opioids, betamethasone or ropivacaine;~* Peri-incisional infection;~* History of stroke or a major neurological deficit;~* Trauma, deformity;~* Psychological problems;~* Extreme body mass index (BMI) (\< 15 or \> 35);~* History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects;~* Patients using systemic steroids;~* Pregnant or breastfeeding;~* Preoperative Glasgow Coma Scale \< 15;~* Participants who have received radiation therapy or chemotherapy preoperatively, or with a high probability to require a postoperative radiation therapy or chemotherapy according to the preoperative imaging.~* Not able to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- The Treatment Group (Type: EXPERIMENTAL): The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
- The Control group (Type: ACTIVE_COMPARATOR): The local infiltration solution in the control group will consist of ropivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-75 years~* Female patients must not be pregnant or breast-feeding~* Patients must be moderately overweight~* All patients must have abnormal cholesterol levels or a history of abnormal cholesterol levels as defined by the protocol.~* Patients taking medication to lower their cholesterol must be willing, in some cases, to discontinue their medications during the study Stable weight (a history of increasing or decreasing no more than 6.6 lbs \[3 kg\]) for at least 2 months prior to the study;~Exclusion Criteria~* Cancer or a history of a cancer within 5 years before screening, other than some skin cancers~* Patients planning elective surgery during the study~* Patients with a history of diabetes mellitus at study onset~* History of intolerance to, or adverse effect from atorvastatin~* History of weight loss due to stomach bypass or eating disorder~* All patients may not have had a stroke, TIA, an acute myocardial infarction, angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy) within 5 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Placebo (Type: PLACEBO_COMPARATOR): None
- MBX-8025 50 mg/Placebo (Type: EXPERIMENTAL): None
- MBX-8025 100 mg/Placebo (Type: EXPERIMENTAL): None
- Placebo/Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): None
- MBX-8025 50 mg/Atorvastatin 20 mg (Type: EXPERIMENTAL): None
- MBX-8025 100 mg/Atorvastatin 20 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who were diagnosed with acute or chronic gastritis in a gastroscopy performed within 7 days prior to administration of this trial.~* At least one or more erosions have been identified on gastroscopy.~* Patients who decided to voluntarily participate in this trial and agreed in writing.~Exclusion Criteria:~* Patients who can not undergo gastroscopy~* Peptic ulcer (except scarring) and reflux esophagitis~* Patients who have had gastric acid suppression surgery or stomach/esophagus surgery (except for simple perforation surgery and appendectomy)~* Patients with a history of gastrointestinal malignancies~* Zollinger-Ellison syndrome patients~* Patient with spontaneous coagulation disorder~* Patients with an allergic or hypersensitive response to a study drug~* Patients with a potential pregnancy.~* Patients who had clinically significant abnormalities in the screening test.~* Pregnant and lactating women~* Those currently taking other study drugs~* patients who were judged to be ineligible for the trial by the principle investigator and the person in charge.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DW1903(Test) (Type: EXPERIMENTAL): once a day, q.d. PO / DW1903 + Placebo of DW1903-R1
- DW1903-R1(Reference) (Type: ACTIVE_COMPARATOR): once a day, q.d. PO / Placebo of DW1903 + DW1903-R1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete